| Document |
Document Title |
|
WO/2011/076736 |
A process for preparing a hydrocarbon or mixture of hydrocarbons comprising the steps of (i) hydrogenating furfural, 5-hydroxymethylfurfural or a mixture of furfural and 5-hydroxymethylfurfural to provide furfuryl alcohol, 2, 5-furandime...
|
|
WO/2011/078387 |
Disclosed is a composition which contains (i) a crosslinkable high-molecular-weight compound that has a crosslinkable group and exhibits either light emitting properties and/or charge transporting properties, and (ii) a crosslinkable low...
|
|
WO/2011/076679 |
The invention relates to a method for producing aromatic and heteroaromatic carbolic acids using CO2.
|
|
WO/2011/073253 |
The present invention provides a method for producing furfural from lignocellulosic biomass material, comprising the steps of: (a) contacting the lignocellulosic biomass material with a mixture comprising water and an organic acid at a t...
|
|
WO/2011/075634 |
The present invention is directed to novel bicyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.
|
|
WO/2011/074550 |
Disclosed is an organic electroluminescent element which has high driving stability and long service life. The organic electroluminescent element can be produced at low cost by forming a light-emitting layer using a composition for light...
|
|
WO/2011/073387 |
A process for the preparation of β,γ-unsaturated-γ,γ-disubstituted esters 1 with high E/Z- and β,γ/α,β-ratios, Formula (1) by reacting at a temperature of between about 130 and 170 degrees centigrade the conjugated malonate Formu...
|
|
WO/2011/071136 |
A therapeutic agent for fibromyalgia, comprising a 5-HT2C receptor agonist as an active ingredient.
|
|
WO/2011/070030 |
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative disease...
|
|
WO/2011/070152 |
The present invention relates to novel antiviral compounds, which are aryl 3-deazauridine analogues at the C3 position, to a method for synthesizing said compounds, as well as to the antiviral uses thereof. The compounds are of the gener...
|
|
WO/2011/070380 |
The subject of the present invention is a novel process for the preparation of N- [2-n-butyl-3-{4-[(3-dibutylamino)propoxy]benzoyl}-1-benzofur
an-5- yl] methanesulfonamide of formula (I) and the new intermediates of the preparation process.
|
|
WO/2011/071048 |
Provided is an agent which is a novel drug for the treatment or prevention of diabetes in that the agent possesses serine protease-inhibiting activity and thereby inhibits an increase in the blood glucose level. The agent is a compound r...
|
|
WO/2011/070459 |
The present invention relates to a novel manufacturing process and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially rennin inhibitors such as Aliskiren. The invention describes a preparation of...
|
|
WO/2011/071503 |
The present invention provides a method for depolymerization of a mixture comprising oligomeric cyclic ethers resulting from copolymerization of at least one tetrahydrofuran and at least one other cyclic ether to recover tetrahydrofuran ...
|
|
WO/2011/069039 |
Disclosed herein are novel hydrazone and diacyl hydrazine derivatives that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Also disclosed are hydrazone and diacyl hydrazine derivatives as potent...
|
|
WO/2011/063500 |
A process for producing furfural involves dehydrating xylose at elevated temperature with a heterogeneous catalyst comprising a sulfonated tetrafluoroethylene-based fluoropolymer-copolymer. The sulfonated tetrafluoroethylene-based fluoro...
|
|
WO/2011/066184 |
The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1 -phosphate receptors.
|
|
WO/2011/061590 |
The present invention relates to carboxamide derivatives of Formula (I), where B1, B2, X, L, n, R, R1, R2, Z1, Z2, Rx and Ry are as defined in the claims, as compounds and compositions for inhibiting Human Immunodeficiency Virus (HIV) an...
|
|
WO/2011/060877 |
The invention relates to organic light emitting devices containing fluorene derivatives and spirobifluorene derivatives as matrix material for phosphorescent emitters.
|
|
WO/2011/062280 |
Disclosed is a method for obtaining an optically active alcohol by highly enantioselective secondary alkylation, while suppressing side reactions. Specifically disclosed is a method for producing an optically active alcohol, which compri...
|
|
WO/2011/059099 |
Disclosed is an aromatic amine derivative represented by the formula N(ArA)(ArB)(ArC), which can be used as an organic EL element material that enables the reduction in voltage and the improvement in luminous efficiency and service life ...
|
|
WO/2011/057332 |
New clerodane compounds isolated from plant material from Dodonaea polyandra are disclosed. The compounds have anti-inflammatory activity. Pharmaceutical and cosmetic compositions containing the compounds, as well as methods of treating ...
|
|
WO/2011/059013 |
Provided is technology for the efficient production of a plant-derived fumaric acid and/or a fumaric acid derivative using as the starting material furfural obtained from renewable plant-based resources that have grown as a result of abs...
|
|
WO/2011/059042 |
Disclosed is a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof, which exhibits excellent long chain fatty acid elongase 6 inhibitory activity and is useful for prevention and ...
|
|
WO/2011/055142 |
The invention provides 1,4-quinones, 1,4-naphthoquinones and their sulphur analogues as inhibitors of hNAT1, an enzyme which is both a diagnostic marker and drug target for breast cancer. Some of the compounds of the invention are also c...
|
|
WO/2011/055115 |
The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
|
|
WO/2011/055529 |
Disclosed is a compound represented by formula (I). (In this connection, the cases where all of the R1-R14 represent hydrogen atoms are excluded).
|
|
WO/2011/054929 |
The invention relates to a method for producing triptolide from a suspension cell culture of Tripterygium sp., to a triptolide-enriched extract obtainable by means of extraction from the culture medium of an in vitro culture of dediffere...
|
|
WO/2011/055142 |
The invention provides 1,4-quinones, 1,4-naphthoquinones and their sulphur analogues as inhibitors of hNAT1, an enzyme which is both a diagnostic marker and drug target for breast cancer. Some of the compounds of the invention are also c...
|
|
WO/2011/055377 |
This invention relates to novel process for the preparation of prostaglandin compounds having formula (K), wherein R is selected from the group consisting of C1-C7 alkyl; C7-C17 aralkyl wherein the aryl group is unsubstituted or substitu...
|
|
WO/2011/056286 |
Presently disclosed are methods and apparatus for separation of reaction products from reaction mixtures in an ionic liquid catalysis process, particularly in conversion of biomass, cellulose, and sugars into chemical intermediates such ...
|
|
WO/2011/056286 |
Presently disclosed are methods and apparatus for separation of reaction products from reaction mixtures in an ionic liquid catalysis process, particularly in conversion of biomass, cellulose, and sugars into chemical intermediates such ...
|
|
WO/2011/050481 |
New eremophilane sesquiterpene lactones were isolated from the extract of the root of Senecio jacobaea having the general formula I. The structures were elucidated by spectroscopic methods including 2D NMR techniques. Methods of using th...
|
|
WO/2011/052388 |
The conversion of naphthol compound (S1) into spirolactone compound (P1) has been conducted by a process which comprises synthesizing a flexible hypervalent iodine compound precursor (iodobenzene derivative) in three steps from 2,6-dihyd...
|
|
WO/2011/052065 |
A process for the purification of tetrahydrofuran from a fluid that contains tetrahydrofuran and includes at least water, dihydrofuran, and butanol as impurities, which comprises: a first distillation step of subjecting the fluid to dist...
|
|
WO/2011/050602 |
Endo-methylene hexahydrophthalic anhydride and production method thereof are disclosed. The endo-methylene hexahydrophthalic anhydride is produced by the following steps: gradually adding maleic anhydride to mixed C5, reacting at 0-5℃ ...
|
|
WO/2011/051225 |
The present invention relates to a process for the total synthesis of epicocconone analogs of formula (I): The invention also relates to novel epicocconone analogs.
|
|
WO/2011/053584 |
A process for upgrading an organic acid includes neutralizing the organic acid to form a salt and thermally decomposing the resulting salt to form an energy densified product. In certain embodiments, the organic acid is levulinic acid. T...
|
|
WO/2011/051853 |
The invention describes a novel technical process and novel intermediates useful for the manufacture of enantiomerically pure 8- aryloctanoic acids of the formula (I) which are pharmaceutically active compounds as rennin inhibitors.
|
|
WO/2011/051102 |
Disclosed is an improved process for the production of phthalic anhydride wherein the spent catalyst is removed from the oxidation reactor tubes more effectively by vacuuming from the top and using a vacuum hose having a tip with an incr...
|
|
WO/2011/052186 |
A fluoranthene compound represented by general formula (1) [wherein Z7 and Z12 are each aryl or heteroaryl; Ar0 is a single bond, aryl, or heteroaryl; R1 to R4 and R6 to R9 are each independently a hydrogen atom, alkyl, cycloalkyl, aryl,...
|
|
WO/2011/047432 |
The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions cont...
|
|
WO/2011/047501 |
2,4,6- or 2,6-alkoxyphenyl dialkylphosphine, its tetrafluoroborate, their preparation method and use are provided. The preparation method is as follows: reacting alkoxybenzene with butyllithium in THF to obtain lithium reagent, then reac...
|
|
WO/2011/046082 |
Provided is an oxime ether derivative represented by formula (I), or a salt thereof. (1) (In the formula, X represents a halogen atom, an alkyl group, or the like; Y represents an oxygen atom or the like; Z represents an oxygen atom or t...
|
|
WO/2011/046569 |
A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the repr...
|
|
WO/2011/045259 |
The present invention relates to aminopropenoate derivatives, their process of preparation, intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of ...
|
|
WO/2011/044990 |
The invention provides a process for preparing 1,2,6,7-tetrahydro-8H-indeno-[5,4-b]furan-8-one (I), said process comprising the steps: (i) subjecting 6-hydroxy-7-allyl-indan-1-one to ozonolysis followed by reduction in the presence of me...
|
|
WO/2011/046954 |
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseas...
|
|
WO/2011/044506 |
The invention provides sulphone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have act...
|
|
WO/2011/042378 |
The invention relates to substituted cyanobutyrates of the formula (I), in which the variables are defined according to the description, to a method and intermediate products for producing the compounds of the formula (I) and the N-oxide...
|
